Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4444306
Max Phase: Preclinical
Molecular Formula: C87H139N23O19
Molecular Weight: 1811.21
Molecule Type: Unknown
Associated Items:
ID: ALA4444306
Max Phase: Preclinical
Molecular Formula: C87H139N23O19
Molecular Weight: 1811.21
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)O
Standard InChI: InChI=1S/C87H139N23O19/c1-6-7-28-56(97-71(114)55-31-18-39-94-55)72(115)99-59(33-20-41-96-87(92)93)74(117)102-61(45-51(2)3)76(119)100-58(32-19-40-95-86(90)91)73(116)98-57(29-14-16-37-88)75(118)106-65(46-52(4)5)83(126)108-42-21-34-67(108)81(124)105-64(49-70(112)113)79(122)107-66(50-111)80(123)104-63(48-54-26-12-9-13-27-54)78(121)103-62(47-53-24-10-8-11-25-53)77(120)101-60(30-15-17-38-89)82(125)109-43-22-35-68(109)84(127)110-44-23-36-69(110)85(128)129/h8-13,24-27,51-52,55-69,94,111H,6-7,14-23,28-50,88-89H2,1-5H3,(H,97,114)(H,98,116)(H,99,115)(H,100,119)(H,101,120)(H,102,117)(H,103,121)(H,104,123)(H,105,124)(H,106,118)(H,107,122)(H,112,113)(H,128,129)(H4,90,91,95)(H4,92,93,96)/t55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-/m0/s1
Standard InChI Key: JJPSBCDYZVNFBY-DOFGFBKQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1811.21 | Molecular Weight (Monoisotopic): 1810.0618 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Furet P, Salem B, Mesrouze Y, Schmelzle T, Lewis I, Kallen J, Chène P.. (2019) Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence., 29 (16): [PMID:31235263] [10.1016/j.bmcl.2019.06.022] |
Source(1):